- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Medicare trust fund extended
A report recently released by the Medicare Trustees projected that the life of the Medicare Trust Fund has been extended until 2023 – eight years longer than had been projected last year. This is a major change from 1993, when President Clinton received the trustees report projecting that Medicare would become insolvent in 1999.
A report recently released by the Medicare Trustees projected that the life of the Medicare Trust Fund has been extended until 2023 â eight years longer than had been projected last year. This is a major change from 1993, when President Clinton received the trustees report projecting that Medicare would become insolvent in 1999.
Despite the good news, however, the president pointed out that Medicare still faces daunting demographic and health challenges. The president also emphasized his comprehensive plan to make Medicare more competitive and efficient; modernize its benefits including adding a voluntary prescription drug benefit; and dedicating part of the budget surplus to meeting the future financial shortfall. Based on preliminary analysis, these policies are projected to extend the life of Medicare beyond 2030.
The report also revealed that Medicare premiums for a couple are $200 lower this year than they were estimated to be in the 1993 Trustees' projections. In 1993, the projected Part B premium for 2000 was $54.50. Today, it is actually $45.50 per month â a 17% decrease from the Trustees' 1993 projections. For an elderly couple, this is an annual savings of more than $200. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
